Trial Summary:

The aim of the trial is to evaluate whether nivolumab plus ipilimumab consolidation treatment after completion of standard chemo-radiotherapy and prophylactic cranial irradiation is superior in terms of overall survival and progression-free survival compared to standard chemo-radiotherapy and prophylactic cranial irradiation alone..

Supported By:

European Thoracic Oncology Platform (ETOP), and Bristol-Myers Squibb

Eligibility:

Radically treated limited-stage SCLC following completion of thoracic radio-therapy concomitant to chemotherapy and PCI

Registration ID:

Participation:

Belgium, France, Germany, Netherlands, Spain, Switzerland, United Kingdom, Australia and New Zealand

Australian Lead Group:

ALTG

Status:

Closed

Activation Date:

07/09/2018

Chairs:

Contact:

stimuli.study@sydney.edu.au